Yes, there is a clinically significant drug-drug interaction between Androcur (cyproterone acetate), Estrofemin (estrogen), and rifampicin in the HRZE regimen for pulmonary tuberculosis.
Rifampicin will substantially reduce the effectiveness of your hormonal therapy (both cyproterone acetate and estrogen), potentially leading to treatment failure of your gender-affirming hormone therapy. This interaction occurs because rifampicin is a potent inducer of cytochrome P450 enzymes and other drug-metabolizing pathways, which dramatically accelerates the breakdown of hormonal medications 1.
The Core Problem
Rifampicin induces CYP450 enzymes (particularly CYP3A4), UDP-glucuronyltransferases, and drug transporters, which increases the metabolism of both estrogen and cyproterone acetate 1, 2. This results in:
- Reduced blood levels of both hormones (potentially 50% or more reduction)
- Loss of therapeutic effect for gender-affirming therapy
- Potential for masculinization/virilization if hormone levels drop too low
- Unpredictable hormone levels throughout TB treatment
The FDA label for rifampicin explicitly warns that it reduces the effectiveness of oral contraceptives and other hormonal therapies, stating that "the reliability of oral or other systemic hormonal contraceptives may be affected" 1. While this warning primarily addresses contraception, the same metabolic pathways affect all estrogen and anti-androgen therapies 3, 4, 5.
What You Need to Do
Option 1: Continue HRZE with Monitoring (Preferred for TB Treatment)
- Complete the full TB treatment as prescribed - tuberculosis is life-threatening and must be treated effectively
- Expect reduced hormone levels during the 2-month intensive phase (HRZE) and 4-month continuation phase (HR)
- Consider increasing hormone doses in consultation with your endocrinologist, though this is challenging because the degree of interaction varies between individuals
- Monitor clinical response (return of masculinizing features, mood changes, physical changes)
- Resume standard hormone dosing after completing TB treatment, as rifampicin's enzyme-inducing effects resolve within 2-3 weeks of stopping the drug
Option 2: Alternative TB Regimen (Only if Medically Appropriate)
This option requires consultation with a TB specialist, as it may compromise TB treatment efficacy:
- Rifabutin instead of rifampicin: Rifabutin is a less potent enzyme inducer and causes smaller reductions in hormone levels 6, 7, though interactions still occur
- Non-rifamycin regimen: Theoretically possible but strongly discouraged - guidelines emphasize that excluding rifamycins "is likely to delay sputum conversion, will prolong the duration of therapy, and possibly result in a poorer outcome" 8
Critical Warnings
Do not stop or reduce your TB medications without medical supervision. Drug-resistant tuberculosis is far more dangerous than temporary hormone level fluctuations. The guidelines are explicit: "a rifamycin should not be excluded from the tuberculosis treatment regimen for fear of interactions" 8.
Do not attempt to compensate by dramatically increasing hormone doses without endocrinology guidance, as this could cause toxicity and the interaction magnitude is unpredictable.
The Other TB Drugs
The other components of HRZE do not significantly interact with your hormones:
- Isoniazid (H): No interaction with hormonal therapy 6, 2
- Pyrazinamide (Z): No interaction with hormonal therapy 6
- Ethambutol (E): No interaction with hormonal therapy 9
Practical Management Strategy
- Inform both your TB physician and endocrinologist about all medications you're taking
- Prioritize TB treatment completion - this is a 6-month regimen that will save your life
- Accept temporary suboptimal hormone levels during TB treatment
- Monitor for masculinizing changes and document them
- Plan for hormone level recovery 2-3 weeks after completing rifampicin
- Consider psychological support if gender dysphoria worsens during treatment
The interaction is unavoidable with standard TB treatment, but tuberculosis poses an immediate mortality risk that outweighs the temporary compromise in hormone therapy effectiveness. Your hormone therapy can be optimized again after TB treatment is complete.